Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis

Targeted Oncology

Volumn 9, Issue 3, 2014, Pages 195-204

  Gartrell, Benjamin A ^a   Ying, Jian ^b   Sivendran, Shanthi ^c   Boucher, Kenneth M ^b   Choueiri, Toni K ^d   Sonpavde, Guru ^e   Oh, William K ^f   Agarwal, Neeraj ^b   Galsky, Matthew D ^f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c Lancaster General Health   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse event; Meta analysis; mTOR inhibitor; Pneumonitis; Solid tumor; Systematic review

Indexed keywords

EID: 84879854909     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0289-2     Document Type: Article

References (35)

1. Guertin DA, Sabatini DM (2005) An expanding role for mTOR in cancer. Trends Mol Med 11:353–361
2. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
3. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535
4. Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36:1–48
5. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
6. Okuno S, Bailey H, Mahoney MR et al (2011) A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer 117:3468–3475
7. Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 22:909–918
8. Pandya KJ, Dahlberg S, Hidalgo M et al (2007) A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer 2:1036–1041
9. Duran I, Kortmansky J, Singh D et al (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95:1148–1154
10. Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central cancer treatment group study. J Clin Oncol: Off J Am Soc Clin Oncol 23:5294–5304
11. Behbakht K, Sill MW, Darcy KM et al (2011) Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a gynecologic oncology group study. Gynecol Oncol 123:19–26
12. Oza AM, Elit L, Tsao MS et al (2011) Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group. J Clin Oncol: Off J Am Soc Clin Oncol 29:3278–3285
13. Soria JC, Shepherd FA, Douillard JY et al (2009) Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol: Off J Eur Soc Med Oncol / ESMO 20:1674–1681
14. Tarhini A, Kotsakis A, Gooding W et al (2010) Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 16:5900–5907
15. Slomovitz BM, Lu KH, Johnston T et al (2010) A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116:5415–5419
16. Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol: Off J Am Soc Clin Oncol 28:69–76
17. Ellard SL, Clemons M, Gelmon KA et al (2009) Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC clinical trials group IND.163. J Clin Oncol: Off J Am Soc Clin Oncol 27:4536–4541
18. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP (2009) A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115:2438–2446
19. \Seront E, Rottey S, Sautois B et al. (2012) Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO
20. Yoon DH, Ryu MH, Park YS et al (2012) Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106:1039–1044
21. Chawla SP, Staddon AP, Baker LH et al (2012) Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol: Off J Am Soc Clin Oncol 30:78–84
22. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281
23. Baselga J, Semiglazov V, van Dam P et al (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol 27:2630–2637
24. Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265
25. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523
26. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529
27. Chawla SP, Blay J, Ray-Coquard IL et al. (2011) Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 29: (suppl; abstr 10005)
28. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol: Off J Eur Soc Med Oncol / ESMO 19:1387–1392
29. White DA, Camus P, Endo M et al (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182:396–403
30. Howard L, Gopalan D, Griffiths M, Mahadeva R (2006) Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. Chest 129:1718–1721
31. Morelon E, Stern M, Israel-Biet D et al (2001) Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 72:787–790
32. Pham PT, Pham PC, Danovitch GM et al (2004) Sirolimus-associated pulmonary toxicity. Transplantation 77:1215–1220
33. Bennett CL, Silver SM, Djulbegovic B et al (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA: J Am Med Assoc 299:914–924
34. Sud S, Douketis J (2009) ACP Journal Club. The devil is in the details…or not? A primer on individual patient data meta-analysis. Annals of internal medicine;151:JC1-2, JC1-3
35. Albiges L, Chamming’s F, Duclos B et al (2012) Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol: Off J Eur Soc Med Oncol / ESMO 23:1943–1953